Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone201-329-7300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$820 million
Profitability
Miscellaneous
Employees1,500
Next Earnings Date8/26/2019 (Estimated)
OptionableOptionable
Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions
What is Phibro Animal Health's stock symbol?
Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."
How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?
Phibro Animal Health declared a quarterly dividend on Tuesday, May 7th. Investors of record on Wednesday, June 5th will be paid a dividend of $0.12 per share on Wednesday, June 26th. This represents a $0.48 dividend on an annualized basis and a yield of 1.65%. The ex-dividend date is Tuesday, June 4th. View Phibro Animal Health's Dividend History.
How were Phibro Animal Health's earnings last quarter?
Phibro Animal Health Corp (NASDAQ:PAHC) released its quarterly earnings data on Monday, May, 6th. The company reported $0.39 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.43 by $0.04. The business earned $205.70 million during the quarter, compared to analysts' expectations of $214.94 million. Phibro Animal Health had a net margin of 8.12% and a return on equity of 33.77%. The company's quarterly revenue was down 1.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.46 earnings per share. View Phibro Animal Health's Earnings History.
When is Phibro Animal Health's next earnings date?
What guidance has Phibro Animal Health issued on next quarter's earnings?
Phibro Animal Health issued an update on its FY19 earnings guidance on Monday, May, 6th. The company provided earnings per share (EPS) guidance of $1.50-1.55 for the period, compared to the Thomson Reuters consensus estimate of $1.68. The company issued revenue guidance of $828-833 million, compared to the consensus revenue estimate of $854.19 million.
What price target have analysts set for PAHC?
3 Wall Street analysts have issued 12-month target prices for Phibro Animal Health's shares. Their forecasts range from $33.00 to $46.00. On average, they expect Phibro Animal Health's share price to reach $40.3333 in the next twelve months. This suggests a possible upside of 38.4% from the stock's current price. View Analyst Price Targets for Phibro Animal Health.
What is the consensus analysts' recommendation for Phibro Animal Health?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 2 sell ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Phibro Animal Health.
Has Phibro Animal Health been receiving favorable news coverage?
Media coverage about PAHC stock has trended very negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Phibro Animal Health earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Phibro Animal Health's key competitors?
Some companies that are related to Phibro Animal Health include TESARO (TSRO), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Reata Pharmaceuticals (RETA), Biohaven Pharmaceutical (BHVN) and Arena Pharmaceuticals (ARNA).
What other stocks do shareholders of Phibro Animal Health own?
Who are Phibro Animal Health's key executives?
Phibro Animal Health's management team includes the folowing people:
- Mr. Jack Clifford Bendheim, Chairman, Pres & CEO (Age 72)
- Mr. Larry L. Miller, Chief Operating Officer (Age 55)
- Mr. Dean J. Warras, Pres of Animal Health & Nutrition - North America (Age 50)
- Mr. Richard G. Johnson, Chief Financial Officer (Age 70)
- Mr. Thomas G. Dagger, Sr. VP, Gen. Counsel & Corp. Sec. (Age 61)
Who are Phibro Animal Health's major shareholders?
Phibro Animal Health's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.40%), Ceredex Value Advisors LLC (2.19%), Renaissance Technologies LLC (1.93%), Dimensional Fund Advisors LP (1.34%), Goldman Sachs Group Inc. (1.24%) and Northern Trust Corp (0.97%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, Gerald K Carlson, Jack Bendheim, Larry Lee Miller and Richard G Johnson. View Institutional Ownership Trends for Phibro Animal Health.
Which major investors are selling Phibro Animal Health stock?
PAHC stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Renaissance Technologies LLC, Charles Schwab Investment Management Inc., New York State Common Retirement Fund, Acadian Asset Management LLC, Citigroup Inc., Marshall Wace LLP and Eagle Asset Management Inc.. Company insiders that have sold Phibro Animal Health company stock in the last year include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras and Jack Bendheim. View Insider Buying and Selling for Phibro Animal Health.
Which major investors are buying Phibro Animal Health stock?
PAHC stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Assenagon Asset Management S.A., Morgan Stanley, Wells Fargo & Company MN, Ceredex Value Advisors LLC, Goldman Sachs Group Inc. and Cambiar Investors LLC. View Insider Buying and Selling for Phibro Animal Health.
How do I buy shares of Phibro Animal Health?
Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Phibro Animal Health's stock price today?
One share of PAHC stock can currently be purchased for approximately $29.14.
How big of a company is Phibro Animal Health?
Phibro Animal Health has a market capitalization of $1.18 billion and generates $820 million in revenue each year. The company earns $64.88 million in net income (profit) each year or $1.74 on an earnings per share basis. Phibro Animal Health employs 1,500 workers across the globe.
What is Phibro Animal Health's official website?
How can I contact Phibro Animal Health?
Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]
MarketBeat Community Rating for Phibro Animal Health (NASDAQ PAHC)
MarketBeat's community ratings are surveys of what our community members think about Phibro Animal Health and other stocks. Vote "Outperform" if you believe PAHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
